Fiasp PBS deletion confirmed
I’ve had a few people ask whether PBS was actually going to de-list Fiasp. None of us wanted it to be real. They have now quietly made the announcement, buried within the monthly list of changes.
Advocacy groups that don’t advocate?
The recent news about Fiasp insulin being removed from the Australian Government’s Pharmaceutical Benefits Scheme (PBS) from April has seen many people in the community ask “Why is Diabetes Australia not saying anything?” The grapevine says that media releases will happen on March 1st (tomorrow). There will at least be a line item hidden in …
Catastrophic Insulin decisions in Australia
I’ve been spending this week in Berlin attending the ATTD 2023 conference. as part of the #dedoc˚ voices. It’s only half done so far. There’s a flood of presentations to attend, study results to absorb, and literally thousands of other people to talk to. It’s very hectic. But in the background I’ve become aware of …
Clinical research news
You may have seen me refer in the past to some of the clinical trials I’ve been involved in. Now it’s time for the next phase of news! The “Baker AAPS” trial In 2019 I started working with the Baker Heart & Diabetes Institute on a clinical trial of the safety and efficacy of the …
Basal impacts of insulin speed
I’ve written numerous times about modelling the activity profiles of various insulins. Telling my oref-based Automated Insulin Delivery (AID) system which insulin I’m using lets it model the current situation (and forecast the future) quite well. We usually think about this in terms of the simple concept of a single bolus: how quickly it starts …
Insulin timings (2022)
Different insulins have effect (and get used up) at different speeds, and modelling this is important for accurate calculation of subsequent insulin doses. Some automated insulin delivery (AID) systems try to determine this themselves (e.g. CamAPS has nowhere for us to tell it which insulin we’re using) and some (e.g. Medtronic and Control-IQ) seem to …